PMID- 23282676
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130104
LR  - 20230404
IS  - 1939-4551 (Print)
IS  - 1939-4551 (Electronic)
IS  - 1939-4551 (Linking)
VI  - 1
IP  - 10
DP  - 2008 Oct
TI  - Anti-immunoglobulin e therapy.
PG  - 174-83
LID - 10.1097/WOX.0b013e318187a310 [doi]
AB  - The importance of immunoglobulin E (IgE) in atopic disorders such as asthma, 
      allergic rhinitis, food allergies, and atopic dermatitis is well established. 
      Elevation of total serum IgE is typically found in many atopic patients, and in 
      predisposed individuals, allergen-specific IgE is produced. The availability of 
      humanized monoclonal antibodies against IgE has provided a new therapeutic option 
      and tool to explore the role IgE in allergic diseases and the effects of 
      inhibiting IgE itself. Omalizumab is a humanized, monoclonal antibody that 
      recognizes and binds to the Fc portion of the IgE molecule. Administration of 
      omalizumab results in a rapid and substantial decrease in free IgE in serum. 
      Consequently, the activity of cell populations involved in allergic inflammation, 
      including mast cells, eosinophils, basophils, and antigen-presenting cells, is 
      affected as well. Clinically, anti-IgE therapy has already been proven to be 
      useful in the treatment of asthma and allergic rhinitis. The aim of this review 
      is to provide an overview of the mechanisms of action of anti-IgE therapy as well 
      as its efficacy in the treatment of allergic diseases, especially asthma. 
      Considerations regarding dosing and safety of omalizumab will be addressed as 
      well.
FAU - Segal, Manav
AU  - Segal M
AD  - From the Division of Allergy and Immunology, Department of Medicine, Creighton 
      University School of Medicine, Omaha, NE.
FAU - Stokes, Jeffrey R
AU  - Stokes JR
FAU - Casale, Thomas B
AU  - Casale TB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World Allergy Organ J
JT  - The World Allergy Organization journal
JID - 101481283
PMC - PMC3651047
EDAT- 2008/10/01 00:00
MHDA- 2008/10/01 00:01
PMCR- 2008/10/01
CRDT- 2013/01/04 06:00
PHST- 2013/01/04 06:00 [entrez]
PHST- 2008/10/01 00:00 [pubmed]
PHST- 2008/10/01 00:01 [medline]
PHST- 2008/10/01 00:00 [pmc-release]
AID - S1939-4551(19)30593-9 [pii]
AID - 1939-4551-1-10-174 [pii]
AID - 10.1097/WOX.0b013e318187a310 [doi]
PST - ppublish
SO  - World Allergy Organ J. 2008 Oct;1(10):174-83. doi: 10.1097/WOX.0b013e318187a310.